Skin allergy testing/delayed response, Intradermal dilution test, Allergies/delayed response/ IgE/allergies
Prevalence and Role of the Delayed Reaction in the Management of the Allergic Patient
Diego Saporta, MD
Introduction
There is a skin response that occurs hours to days after the injection of an allergen into the skin. In this article the information presently available about this delayed skin response will be discussed, followed by the author’s experience. An analysis of the prevalence of these responses during skin allergy testing at the author’s office will be presented, including information about the role of these delayed responses in the management of the allergic patient.
Background
Skin allergy testing has been in use since 1865 when Charles H. Blackley performed what later came to be known as the scratch test. He abraded his own skin and applied pollen over the abrasions, which resulted in intense itching and inflammation.1 In 1926 the prick test was described by Lewis and Grant,2 who also described the skin response that came to be known as the “wheal and flare” reaction, which is well known to all allergy practitioners.3
In 1930 French Hansel described an intradermal test using multiple 1:10 dilutions of the same extract. This provided a greater degree of information than the intradermal test with a single dilution used by the general allergists.4 Herbert Rinkel modified this test in 1935 by using 1:5 dilutions. With this modification he observed that the skin response was now predictable through three or four dilutions in 72% of the patients. This increased the accuracy and safety of the test and also allowed for the diagnosis of skin reactivity to the allergen at very low and at very high allergenic concentration while minimizing the risk of a severe reaction.4 Injecting a single dose of the allergen can be dangerous in a very sensitive (very reactive) patient.
The modified test as described by Rinkel became the Skin End Point Titration or SET, which at the present time is called Intradermal Dilutional Test or IDT. The IDT is used by ENT allergists and other practitioners usually trained at the PAAS or AAEM courses (see Sidebar 1).
The early workers also observed that introducing an allergen into the skin of an allergic patient could provoke not only an immediate skin response (ISR) but also a late skin response lasting from hours to days. This reaction could affect the skin and/or trigger constitutional symptoms also lasting from hours to days.5
The ISR develops rapidly after the injection of the allergen into the skin. The maximum size occurs 10-15 minutes after the injection and then disappears. After its resolution a second skin reaction can develop. According to the time when this skin response develops, it is called Late Skin Response (LSR)—developing over 6 to 24 hours after the injection—or Delayed Skin Response (DSR)—developing 48 hours or later after the injection. This type of responses can develop even after negative tests (no ISR preceding the delayed response).6,7
It is suggested that the clinical relevance of the late skin response “is not yet fully established”8; but as stated, there is evidence that symptoms can develop when this LSR develops5 and that it may be more important than the ISR when considering symptom development.9
The LSRs and the DSRs are described as well-identified and different skin responses:10-12
-
LSR: skin reaction that develops after the ISR, plateaus between 6 and 12 hours, is present at 24 hours, and usually disappears by 48 hours after the skin challenge. It is characterized by edema, mixed cellular infiltrates including macrophages, eosinophils, neutrophils, tryptase positive mast cells, Langerhans cells, large numbers of basophils and T cells, and sometimes by fibrin deposition.10
-
DSR: cell mediated delayed reaction, including lymphocytes and macrophages, that begins within hours, reaches maximum size in 48 hours but can persist for a week or longer and can even blister in some cases. 11
However, the differences between both types of delayed skin reactivity may blur, not only clinically, but also histologically. It has been suggested that the clinical appearance of the LSR and the DSR may not be completely distinguishable.12 The LSR could be the consequence of a Type III hypersensitivity reaction (with deposition of immune-complexes),13 but a complex cellular infiltration of mononuclear cells is commonly described.14,15,16 This cellular infiltrate starts to accumulate four-to-eight hours after the skin test reaching maximal intensity at two-to-three days.15 The infiltrate is composed of a variety of cells including T-cells, macrophages, eosinophils, neutrophils, Langerhans cells, and even mast cells and basophils.15,17
The concept that a delayed type of skin response can occur after a skin test (with or without development of an immediate reaction or positive test) is clear. As described above, differentiating between an LSR and a DSR is more elusive. It appears that after the initial skin challenge there is a complex immunological process. This process starts only a few hours after the allergen injection and continues to progress over many hours and even several days, with the possibility of triggering systemic clinical symptoms. These descriptions fit better the concept of a continuum that starts developing just hours after the injection of the allergen and continue to develop over a long time.
What is more difficult to understand is how a process that involves all cells of the immunological system (including both, the innate and the adaptative immune system) is even considered to be exclusively dependent on the presence of IgE.5,18,19 These descriptions are more in agreement with the idea that a skin response after an allergen challenge is likely to involve several or all of the four mechanisms of hypersensitivity described by Gell and Coombs.20
A Clinical Significance for the Delayed Reaction?
Published literature suggests that the late skin responses should not be disregarded. The presence of delayed skin reactivity, “which does not include IgE” could be protective21and the size of the delayed reaction could be related to the health and immunocompetence of the individual. 22, 23 It has been reported that immunotherapy administration significantly decreased the incidence of both the ISR and the LSR24 and also decreased the incidence of both the immediate and late onset of asthma symptoms.25
Therefore, LSRs should be considered when managing a patient with allergic disease as allergens can cause significant immunological reactions without necessarily provoking an immediate (Type I) hypersensitivity reaction.
Dr. Richard Jaekle observed that fungal allergens from the TCE mix (Trichophyton, Candida and Epidermophyton) triggered symptoms when tested on the skin of the allergy sufferer. He separated the TCE into its individual mold components and tested each mold separately. When DRs that triggered symptoms developed, he was able to use this information to formulate a vaccine with successful therapeutic effect.26
Dr. Alan McDaniel found that intradermal skin tests for molds showed greater prevalence of late and delayed skin reactions than other allergens.27 He also observed that the wheal diameter for the delayed reaction grew by 3 mm when comparing progressively stronger concentrations of the same allergen.27
Author’s Experience
Clinical observations are in agreement with what is described in the literature: Late-onset skin responses can develop after a skin test. They are frequently present at 24 hours. Less frequently they develop at 48 hours and rarely they can persist for days or even weeks. They can follow a positive skin test (ISR) or a negative skin test (no ISR).
Except for the timing when the measurement is done, it is not possible to differentiate from the clinical point of view, between a LSR and a DSR. Both appear to play a similar role in the clinical management of the allergic patient. For this reason, we decided to address the LSR and the DSR simply as “delayed reactions” (DRs) without differentiating when they develop. Published literature appears to support this decision as the delayed response is generally described as a reaction that starts a few hours after the injection and extends through a rather long period of 72 hours or more.11,15
The significance of the delayed reaction for the practicing allergist in the clinical context is two-fold:
-
When a DR develops the patient may complain of itching and dry skin (rarely blistering or long-standing discoloration) at the site of the skin test;
-
More importantly, vaccine formulas that contain allergens that triggered DRs will favor development of local arm reactions (LARs) at the site of the vaccine injection. These LARs are characterized by swelling, induration, and pain which can be significant. This pain is one of the most common causes for immunotherapy discontinuation. Severe cases of LARs after an immunotherapy injection can develop an eczematoid appearance of the skin and can even blister. Rarely they can leave a persistent discoloration of the skin lasting for a long time.
When a decision is made to treat a patient with immunotherapy, the test will provide information on how to formulate the allergy vaccine. For this formulation to be effective the type of test used is important.28 Immunotherapy results are best when a strong dose of allergen is administered through a process of dose escalation over time.29 It is not uncommon to develop a LAR30 or just pain at the injection site when dose is advanced.
Since early in the author’s practice, it was observed that when DRs were present, the incidence of LARs during dose escalation was more prevalent. As stated, these LARs make dose escalation difficult. While there are alternative ways to administer immunotherapy that do not involve weekly injections (SLIT31 and LDA32), the majority of the patients elect to be treated with an insurance reimbursable service and this is only the subcutaneous injection immunotherapy (“allergy shots”). Therefore, learning to manage the DR is important to treat patients that develop LARs.
Dr. McDaniel’s advice to selectively dilute the allergens that gave a delayed reaction forms the base for the management in the patient with DRs who is about to receive immunotherapy. The result of such intervention was a marked decrease in the number of LARs so that the quality of patient’s management improved. (For further information see Sidebar 2: “How we manage the delayed reaction”). While LARs still occur, they are not nearly as frequent as early in the practice.
The author strongly agrees with the concept that allergens that produce delayed skin responses can produce symptoms in the affected patient. The following observations appear to support such contention:
-
The author has treated a group of 10 patients, at no cost to the patients, who had an IDT with only delayed reactions; and he observed clinical improvement in all of them. (Obtaining a full IDT with only DRs is a rare occurrence).
-
The results of immunotherapy treatments clearly improved after the information provided by DRs that developed after a negative skin test (no ISR) was incorporated into the vaccine formula.
-
The author managed a patient who, 24 hours after a completely negative intradermal test, developed diffuse urticaria and an asthma attack. When this patient presented to the office the day after the IDT, she was noted to have DRs at the site of dust and dander tests.
These unpublished observations strongly suggest the role of the DR in symptom-provocation and support the decision to incorporate the information provided by the DR in the formula of the vaccine so that allergy vaccines include a) allergens with ISRs only, b) allergens with ISRs and DRs, c) allergens with DRs only.
Clinical Observations About the Delayed Reaction
The intradermal dilutional test uses six dilutions of each allergen. The number of the dilution expresses how many times the allergen extract was diluted, so the dilution #6 is the weakest. The dilutions #1; #2 and #3 then, carry a stronger concentration of allergen while the dilutions #4, #5 and #6 carry a weaker concentration of allergen. An allergen usually requires two-to-four injections to determine if that allergen is either reactive (positive) or non-reactive (negative). (See Sidebar 1 for more information on the IDT). The DR can occur after a positive test (ISR) or after a negative skin test (no ISR).
The majority of the DRs are observed with the three stronger dilutions (#1, #2 or #3) but sometimes DRs are observed with weaker dilutions (#4, #5 or even #6). When a DR develops after a positive test, it usually involves the confirmatory reaction or the first reactive wheal and the confirmatory reaction. Usually DRs are present at 24 and frequently at 24 and 48 hours. Finding DRs only at 48 hours is not common, and finding DRs lasting days to weeks or injuring the skin (discoloration or blistering) is rare. Frequently DRs can develop over two consecutive dilutions in the skin test (for example dilutions #2 and #1). It is uncommon to find DRs affecting three consecutive dilutions and extremely rare to find DRs over four consecutive dilutions.
Monitoring for the presence of DRs requires training. It is sometimes difficult to decide if a DR is present, as erythema may not develop so it may be difficult to see. In these cases, the DR is sometimes better evidenced by palpation. The “injury” of the needle stick is usually evident for several days, and it should not be confused with a DR. The measurement of the diameter of the DR is difficult as the border is not well formed. This is why it is difficult for patients to self-report the presence of DRs.
Prevalence of Delayed Reactions After Intradermal Dilutional Test
Objective: To determine 1) the prevalence of DRs after intradermal testing with multiple dilutions (IDT) in a private practice setting. 2) which allergen groups (dust-dander, molds, pollens) are more likely to elicit a DR, 3) which of the dilutions used in the IDT are more likely to have a DR.
Methods: Charts containing the skin tests of patients receiving immunotherapy treatment were considered for inclusion regardless of sex, age, or presence of respiratory symptoms.
Two groups of charts were included because for many years our patients were encouraged to comply with a 24-hour and a 48-hour check after the intradermal test. Because of lack of compliance with the second check and time constraints at the office, in the last few years patients are only encouraged to come for the 24-hour check. The groups of charts included the following:
-
A group of 100 charts was randomly selected by pulling one out of every four charts from the active-patients cabinet. Charts were selected if they contained a complete test that included all panels routinely tested at our office and the patient had come to the office to determine the presence of delayed reactions for at least one of the panels. Patients are tested in four sessions. Each session tests for 1 panel: Dust and Dander; Mold; Tree-pollens; Grasses and Weed-pollens (see appendix 3 for a complete list of the allergens tested). This group of 100 charts was used to evaluate results of the 24-hour check. The two pollen-panels are considered separately to determine compliance but then they are combined in a “pollen group” to study prevalence of DRs.
-
The second group of charts was used for the 48-hour control. Charts were randomly pulled out and included for review if they contained at least one panel with a 48-hour control. A group of 71 panels was gathered from 38 different charts that met the criteria.
Information was anonymously charted in an Excel spreadsheet and data was then analyzed.
Results: 24 hour-check. There were 100 charts containing a complete intradermal dilutional test. There were 4 panels in each one, tested on separate days. The 400 panels contained a total of 5600 individual skin tests out of 5600. (See Sidebar 3 for complete information on all the allergens in each panel).
Of the 100 patients, there were 38 males and 62 females aged 8-72 years (average 36). There were 28 patients younger than 18 years of age.
Compliance: 15/400 panels lacked a 24-hour control leaving a total of 385 panels available for analysis. Overall compliance with the 24-hour check was 96.3% (385/400). The number of individual allergen tests available in the 385 remaining panels was 5077.
Table 1 shows distribution of the non-compliant cases. The panel for dust and dander shows the least number of non-compliant cases. This could be explained by the fact that this panel is the first one tested in the overwhelming majority of the cases. It is expected that compliance will be better with the first set of tests.
Delayed reactions: There were 571 delayed reactions (DRs) in the 5077 individual tests for an incidence of 11.2% DRs for any allergen tested with an IDT (Table 2). DRs were more prevalent with allergens of the Dust and Dander group and least prevalent with allergens from the Mold group. (Table 2).
Delayed Reactions after a negative skin test: When the skin test is negative, there will be no growth of the wheal at the injection site (no ISR). Regardless, a DR can develop 24 hours later (or more). Table 2 shows that 184/571 or 32.2% of DRs occurred after a negative skin test. This is more likely to occur with Mold allergens. In this series, while the occurrence of DRs in the mold group was 8.4%, more than 50% of these DRs followed a non-reactive (negative) mold test.
Delayed Reactions by Dilution: The IDT uses six dilutions. Dilution #6 (D6) is the weakest dilution (carrying the least amount of allergen) and Dilution #1 (D1) is the strongest one (carrying the most concentration of allergen). The majority of the positive results (ISRs) with the IDT are seen with the stronger dilutions (D3, D2, D1).33 The prevalence of DRs follows a similar pattern (Table 3): Most of the DRs developed with dilutions #2 and #1 for all groups. This is more evident when the data in both dilutions was combined. The incidence of DRs markedly decreased in the weaker dilutions.
Dilution #5 is almost never used during testing. This explains why in this series no results were found with this dilution.
Molds appeared to have a higher percentage of DRs in the stronger dilutions (93.6 % for D1+2). Pollens appeared to have a higher rate of DRs at Dilution #6 (16/18 DRs at dilution #6). A possible explanation for this is that pollens are usually the most reactive and molds are the least reactive of the allergens so it is common to stop the test for pollen (or for dust and dander) at a weaker dilution while mold testing usually progresses to very strong dilutions.
Diameter of the Delayed Reaction in reference to the immediate test result: When more than one DR for a tested allergen was encountered, the diameter of the DR was larger at the stronger dilution (the one containing more concentrated allergen). The diameter of the DR was compared to the diameter of the wheal at the time of the test. In the cases where more than one DR developed in a single allergen test, the DR with the largest diameter was chosen for this analysis. The diameter of the DR can be smaller, larger or the same as the wheal at the time of the test. As seen in Table 4, there was a tendency for the DR diameter to be smaller than the wheal at the time of the test. This was more evident for pollens.
Results: delayed reactions at 48-hour check. The 71 panels with 48-hour control information provided 853 individual allergen tests. All patients that came for the 48-hour control had previously come at 24 hours.
Table 5 shows there were 222 DRs present in the 853 individual allergen tests for a percentage of 26.0%. The majority of the DRs (87.4%) were present at 24 hours, 61.3% were also present at 48 hours. There is a subgroup of 28/222 DRs (12.6%) where the DRs were present only at 48 hours. From these, 12/28 (42.9%) occurred in a single pollen panel.
Conclusions
Delayed reactions after an intradermal dilutional test are likely to develop in 11.2% of the tests.
They can develop not only with the perennial type of allergens (dust, dander or mold) but also with pollen allergens.
DRs are clearly more prevalent when a large amount of allergen is injected (Dilutions #1 and #2).
A large percentage of DRs develop after a negative skin test (184/571 or 32.9 % of DRs of which 52.6% occurred in the mold panel). This is an important number that appears to be more significant for mold allergens.
When reactions are present at 48 hours, the majority are concomitant with the 24-hour event; but there is a subgroup of reactions that are present only at the 48-hour check. This happened in 12.6% of the DRs available for evaluation.
Discussion
Delayed reactions are not unusual. Not testing on dilutions #1 and #2 will prevent the practitioner from acquiring very important information. Many ENT allergists do not test for dilution #1. Not testing for dilution #1 will miss not only the immediate reactivity at this dilution but also approximately 50% of the information related to the presence of DRs. General allergists, when they perform an intradermal test, only test for a dilution weaker than the #2 of the IDT (an allergenic concentration between dilutions #2 and #3).8 Not testing for dilutions #1 and #2, beyond missing the information pertaining to the immediate reactivity, will miss more than 80% of the DRs and this can account for a difference in treatment results.28
A proper evaluation for the development of DRs is complex and time consuming. In our experience it requires properly trained personnel. From this review it is clear that the 24-hour check is very important as it provides most of the information pertaining to DRs. A 48-hour check can provide additional information. In our series it amounted to 12.6%. Because almost half of the DRs at 48 hours were found in a single tested panel, which in our experience is not a frequent observation, potentially the value of a 48-hour check could be even smaller. In the author’s opinion, the fact that DRs can develop at 48 but not at 24 hours should be considered to emphasize to the patient the need for a 48-hour check if the 24-hour check did not show any DRs. Otherwise the information obtained at 24 hours appears to be sufficient to handle the clinical aspects of immunotherapy administration.
The prevalence of DRs in the 100-chart group (5077 individual allergens tested), was 11.2%. In the group of tests used to evaluate the DR at 48 hours (only 853 individual tests) the prevalence of DRs was 26.0%. Probably 11.2% represents more accurately the rate of DRs after IDT.
When performing an IDT in the clinical setting, not all the available dilutions are necessarily used. When evaluating the number of DRs that occur with each dilution, obviously the results will be influenced by the number of times each dilution was used for testing. Ultimately a properly designed study should be planned using all the dilutions and having all participants comply with a 24- and a 48-hour check to gather complete information on the relationship between allergen concentration and prevalence and diameter of the DRs associated with each dilution and to completely assert the significance (or lack of) the 48-hour control after a 24-hour control. To validate the findings presented here, it should be important that these results be re-evaluated in a multi-office study. The caveat is that testing methods should be consistent using the intradermal dilutional test and testing for dilution #1 (the most concentrated of the allergen dilutions). 28
Despite these shortcomings, it is clear that the DR is more prevalent with stronger (more concentrated) allergen. The study also suggests that when DRs occur with weaker concentrations, pollens probably are more prevalent.
In agreement with published data5 we also observed that the diameter of the DR follows the diameter of the ISR. This is more evident when there are DRs on consecutive dilutions with increasingly stronger allergen concentration. As expected, the diameter of the ISR increases the more concentrated the injected allergen and the same happens with the diameter of the DR.
It has been suggested that DRs occur mainly with mold allergens6, 27 and some indoor allergens like roaches.6 It is accepted that DRs can also occur with pollens5 but this chart review clearly suggests that DRs after pollen tests is a common occurrence (Table 2). This analysis has not been done allergen by allergen, therefore it does not rule out the possibility that a single allergen is more likely to elicit a delayed reaction than others.
Beyond the controversy of the DR being related to IgE or not, there is clinical usefulness in checking for the development of DRs after a skin test. A patient that develops DRs is clearly more difficult to treat with immunotherapy. It is important to be aware that all allergens should be checked for the potential presence of a delayed reaction. The information provided by the DR helps attain better results with less problems and more tolerability by the patient. (For further information on this, see Sidebar 2: How we manage the delayed reaction).
The vast majority of the allergy-practitioners disregard the clinical usefulness of the DR as it does not conform to the idea that allergy is related exclusively to the presence of IgE.20 While the answer to why this point of view is so strongly held is elusive, the discovery of IgE in 1965 may play a role.34 This immunoglobulin was found only in patients with allergies. This may explain why it was assumed that allergy is exclusively an IgE-mediated phenomenon disregarding the fact that there are several types of hypersensitivity reactions as described by Gell and Coombs.35 There are experiments where IgE triggers not only an ISR but also a LSR.5 Concluding that the LSR is related only to the presence of IgE, excludes the concept that after an initial Type I hypersensitivity reaction, the other mechanisms of hypersensitivity can develop, following the complex cascade of substances liberated and produced after the initial stimulus. The view that allergy is exclusively an IgE-related phenomenon is widely accepted even though there is ample evidence in the literature of non-IgE immunological phenomena.36,37,38,39
Supporting the rationale that the allergic response is a complex one, probably involving multiple mechanisms at the same time, is the common observation that a patient with a clear history of allergic disease can have a negative “RAST”40 test. The “RAST” test that is usually reimbursed by insurance carriers measures only for the presence of IgE. While this test is accurate for the measurement of IgE, finding a negative test is not uncommon. When a patient with clear clinical history of allergic disease and a negative IgE “RAST” is tested with an IDT,the patient will, in my experience, have a positive skin test. Obtaining a positive skin test (development of ISRs) in the face of a negative “RAST” test implies that at least some of the ISRs develop independently of an IgE-mediated mechanism.
The field of immunology is in constant evolution. It has been suggested that human immune responses may not adhere to classical Th1 or Th2 profiles. T cells from different subjects and even within the same individual may exhibit multiple specificities with Th1 and/or Th2 characteristics and the complexity of cytokine responses may reflect the genetic heterogeneity of humans compared with other animal systems that have been used to establish the Th1/Th2 paradigm.41
Different allergens were identified in a dermatophyte that are capable of eliciting either an ISR or a delayed type of reactivity.42 The apparent difference between the LSR and DSR 10-12 may be related to the portion of the allergen interacting with the immunological system.
References
-
www.immunology.org/skin-allergy-test-1865. Accessed December 14, 2019
-
Lewis T, Grant RT. Vascular reactions of the skin to injury. Heart 1926:13:219-25, in: Boyles JH. A comparison of techniques for evaluating IgE-mediated allergies. ENT-Ear, Nose & Throat Journal. April 2011; 90(4):164-169.
-
Reed WB, Pidgeon J, Becker SW. Studies on the triple response of Lewis in patients with spinal cord injury. Journal of investigative dermatology. October 1960:135-143.
-
Nadarajah R, Rechtweg JS, Corey JP. Introduction to Serial Endpoint Titration.
Immunology and Allergy Clinics. 2001; 21(2): 369-381.
-
Gleich GJ. The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? JACI. 1982;70:160.
-
Lin RY. Delayed hypersensitivity to pollen skin prick tests and seasonal rhinitis. J Allergy Clin Immunol. 1995;95(4):1–3.
-
Pelikan Z. Rhinitis, secretory otitis media and sinus disease caused by food allergy. In: Brostoff J, Challacombe SJ. Food allergy and intolerance, 2nd edition. London. Saunders. 2002; p. 510.
-
Bernstein LI, et al. Allergy Diagnostic Testing: An Updated Practice Parameter. Annals Allergy, Asthma, Immunol. March 2008; 100(3) Supplement 3.
-
Larsen GL. Late-phase reactions: Observations on pathogenesis and prevention. JACI. 1985;76(6):665-669.
-
Bernstein LI, et al. Allergy Diagnostic Testing: An Updated Practice Parameter. Annals Allergy, Asthma, Immunol. March 2008;100(3) Supplement 3. (Summary Statements 37 and subsequent).
-
Ibid. (Summary Statements 62 and subsequent).
-
Ibid. (Summary Statements 73).
-
Pepys J, Turner-Warwick M, Dawson PL, Hinson KFW. Arthus (type III) skin test reactions in man. Clinical and immunopathological features, in Excerpta Medica International Congress Series, Allergology, Proceedings of the Sixth Congress of the International Association of Allergology. 1968;162:221.
-
Friedlaender MH, et al. Histopathology of delayed hypersensitivity reactions in the guinea pig uveal tract. Invest Ophthalmol. Visual Sci. April 1978;17(4):327-335.
-
Dvorak HF, Martin C, Dvorak AM. Morphology of delayed-type hypersensitivity reactions in man. Journal of Investigative Dermatology. 1976;67(3):391-401.
-
Gulliver EL, et al. Histopathological Characterization of Cutaneous Delayed-type Hypersensitivity and Correlations with Intestinal Pathology and Systemic Immune Responses in Sheep with Paratuberculosis. J Comp Pathol. 2015 Aug-Oct;153(2-3):67-80.
-
Tsicopoulos A, Fahy O, Tonnel AB. Delayed-type hypersensitivity reactions to nominal protein antigens and to environmental allergens: similarities and differences. Eur J Dermatol. 1999;9(4):261–268.
-
Solley Go, et al. Late phase of the immediate wheal and flare skin reaction: its dependence on IgE antibodies. J Clin Invest. 1976;58:408.
-
Dolovich J, et al. Late cutaneous allergic responses in isolated IgE dependent reactions. J Allergy Clin Immunol. 1973;52:38–46.
-
McDaniel AB. Fungus allergy and hypersensitivity in mold-related illness. Townsend Letter. 2016 April; 393: 42-8.
-
Woodfolk JA, Platts-Mills TA. Diversity of the human allergen-specific T cell repertoire associated with distinct skin test reactions: delayed-type hypersensitivity-associated major epitopes induce Th1- and Th2-dominated responses. J Immunol. 2001 Nov 1;167(9):5412-9.
-
Hansen KN, Heltberg I, Hjelt K. Sensitivity to tuberculin and sensitins from atypical mycobacteria (M. chelonae subsp. Abscessus, M. avium, M. intracellulare, M. scrofulaceum) in 100 Danish school children. Dan Med Bull. 1989;36(4):399–401.
-
Maher J, et al. Skin anergy and tuberculosis. Respir Med. 1992;86(6):481–484.
-
Nish WA, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol. 1994;93:484-93.
-
Van Bever HP, et al. Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen. Allergy. 1988;43: 378-85.
-
Jaeckle RG. Delayed Skin Reactions. Presented at the Annual Meeting of the Pan American Allergy Society. August 18,2018. San Antonio, Texas
-
McDaniel AB. AAOA Annual Meeting. New Orleans, LA; September 1995
-
Saporta D, Hurst D. Management of the allergic patient: The role of different diagnostic tests. Townsend Letter. April 2018:52-55.
-
“Optimal Dosing” in American Academy of Otolaryngology, Clinical Care Statements. January 2105. Page 14.
-
Cox L, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;121:S1-S55.
-
Saporta D. Sublingual Immunotherapy: A Novel, Albeit Not So New, Immunotherapy Treatment Modality. Am J Rhinology. 2008;22: 253-257.
-
Saporta D. Low-Dose Allergen Immunotherapy (LDA) vs. Subcutaneous Injection Immunotherapy: A Comparative study. Townsend Letter. June 2015; 62-66.
-
Saporta D, Hurst D. Increased Sensitization to Mold Allergens Measured by
Intradermal Skin Testing following Hurricanes. Journal of Environmental and Public
Health. 2017;Article ID 2793820.
-
IgE was simultaneously discovered in 1966 and 1967 by two independent groups, one in the US (Ishizaka) and one in Sweden (Johansson).
-
Ishizaka K, Ishizaka T, Hornbrook MM (1966). Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol. 97 (1): 75–85.
-
Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 1967; 13:381-94. https://en.wikipedia.org/wiki/Immunoglobulin_E#cite_note-11. Accessed December 15, 2019
-
Gell PGH, Coombs RRA. Clinical aspects of immunology. Oxford. Blackwell Scientific Publications. 1963.
-
Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitopeinduced late asthmatic reactions. J Exp Med. 1999;189(12): 1885–1894.
Cianferoni A. Non-Ige Mediated Food Allergy. Curr Pediatr Rev. 2019 Oct 30.
-
Nowak-Węgrzyn A, et al. Non-IgE-mediated gastrointestinal food allergy. J Allergy Clin Immunol. 2015 May;135(5):1114-24.
-
Jönsson F, et al. An IgG-induced neutrophil activation pathway contributes to human drug induced anaphylaxis. Sci Transl Med. 2019 Jul 10;11(500). pii: eaat1479.
-
RAST (
R
adio
A
llergo
S
orbent
T
est) implies use of radioactive reagents. At this time most of these blood tests use other technologies like ELISA
-
Woodfolk J.A, et al. Definition of a Trichophyton protein associated with delayed hypersensitivity in humans: evidence for immediate (IgE and IgG4) and delayed type hypersensitivity to a single protein, J Immunol. 1996 Feb 15;156(4):1695-701.
-
Woodfolk JA, et al. Trichophyton Antigens Associated with IgE Antibodies and Delayed Type Hypersensitivity. Sequence homology to two families of serine proteinases. Journal of biological chemistry. 1998;273(45):29489–29496.
Sidebar 1: Intradermal Dilutional Test (IDT)
For further information on how to perform the IDT or how to incorporate allergy management into the practice, consider a course in any of the following organizations:
American Academy of Otolaryngic Allergy (AAOA) offers courses on inhalant and food allergies for ENT practitioners. Visit aaoaf.org.
Pan American Allergy Society (PAAS) offers courses on inhalant and food allergies to any interested practitioner. Visit paas.org.
American Academy of Environmental Medicine offers courses on inhalant and food allergies to any interested practitioner. Visit aaemonline.org.
The following are books that offer in depth information on allergy and immunotherapy with the approach presented here:
-
Krouse JH, et al (eds.). Allergy and Immunology, an Otolaryngic Approach. Philadelphia, PA: Lippincott Williams & Wilkins, 2002.
-
King HC, Mabry RL, Mabry CS. Allergy in ENT Practice. New York: Thieme Medical Publishers, 1998.
-
Mabry RL. Skin End Point Titration, AAOA Monograph Series. New York: Thieme Medical Publishers, 1994.
Sidebar 2: How We Manage the Delayed Reaction
This information is of interest for those practitioners that provide immunotherapy.
After the intradermal test is completed, the patient is asked to come to the office for a 24- and a 48-hour control. In these controls the tested area is examined for the presence of DRs. This is done visually and by palpation. The average of the 2 orthogonal diameters is obtained and recorded next to the immediate test results. Black color is used to record the immediate test results (either negative or positive), blue for DRs at 24 hours and red for DRs at 48 hours. To measure the wheal diameter, it sometimes helps to use a ball pen to slide over the normal skin until the tip of the pen “locks” in the periphery of the DR.
If no DR develops, a checkmark with the corresponding color is placed so that there is certainty that the control was done and there were no DRs.
Any DR with a diameter of 5 mm or larger is recorded. According to the DR-diameter, the concentration of the allergen to be mixed into the vaccine formula is selectively diluted as follows:
-
DR diameter of 5 mm or 7 mm: use allergen at 2 dilutions weaker
-
DR diameter of 9 mm: use allergen at 3 dilutions weaker
-
DR diameter of 11 mm or 13 mm: use allergen at 4 dilutions weaker
-
DR diameter >13 mm: use allergen at dilution #6
When the DR is present over several dilutions of the same tested allergen: choose the DR present at the weakest dilution for above calculations.
When the diameter of the DR in the same dilution is different at 24 and 48 hours: Choose the larger diameter DR for above calculations.
Sidebar 3: List of Allergens Tested by IDT
DUST AND DANDER |
|---|
| Dermatophagoides Pteronyssinus |
| Dermatophagoides Farinae |
| Cat |
| Dog |
| American Roach |
| German Roach |
MOLD |
| Alternaria |
| Aspergillus |
| Chaetomium |
| Cephalosporium |
| Cladosporium |
| Curvularia |
| Epiccocum |
| Fusarium |
| Helminthosporium |
| Mucor |
| Penicillium |
| Phoma |
| Pullularia |
| Rhodotorula |
| Rhizopus |
| Stemphyllium |
| Candida |
| Trichophyton |
| Epidermophyton |
POLLENS-TREES |
| Ash |
| Birch |
| Cottonwood |
| Elm |
| Hickory |
| Mulberry |
| Oak |
| Pine |
| Privet |
| Red Cedar |
| Red Maple |
| Sycamore |
| Walnut |
POLLENS-GRASS |
| Bahia |
| Bermuda |
| Johnson |
| Timothy |
POLLENS-WEEDS |
| Cocklebur |
| English Plantain |
| Goldenrod |
| Kochia |
| Lambs Quarter |
| Marsh Elder |
| Nettle |
| Pigweed |
| Ragweed |
| Sheep Sorrel |
TABLES
Table 1. Non-Compliance with 24-Hour Check.
Panels |
# |
Ratio (%) |
|---|---|---|
DD |
2 |
2/15 (13.3) |
Mold |
6 |
6/15 (40.0) |
Pollen |
7 |
7/15 (46.7) |
Total |
15 |
15/15 (100.0) |
DD: Dust and dander panel.
Mold: Mold panel.
Pollen: Pollen group, including trees, grasses and weeds
#: Number of panels not compliant with a 24-hour check
Ratio (%): each panel /total of 15 non-complaint cases (Percentage)
Table 2. Incidence of Delayed Reactions.
Group |
DD |
M |
P |
Total |
|---|---|---|---|---|
# Tests |
588 |
1784 |
2705 |
5077 |
# DR (%) |
122 (20.7) |
149 (8.4) |
300 (11.4) |
571 (11.2) |
No ISR (%) |
36 (29.5) |
77 (51.7) |
71 (23.7) |
184 (32.2) |
# Tests: Number of tests available for analysis.
# DR (%): Number of Delayed Reactions (percentage)
No ISR (%): Delayed Reactions that developed after a negative skin test (Percentage)
DD: Dust and dander group.
M: Mold group.
P: Pollen group, including trees, grasses and weeds
Table 3. Delayed Reactions by Dilution
Group |
#T |
D6 (%) |
D5 (%) |
D4 (%) |
D3 (%) |
D2 (%) |
D1 (%) |
D1+D2 (%) |
|---|---|---|---|---|---|---|---|---|
DD |
141 |
2 (1.4) |
0 (0) |
13 (9.2) |
4 (2.8) |
66 (46.8) |
46 (39.7) |
122 (86.5) |
Mold |
155 |
0 (0) |
0 (0) |
9 (5.8) |
1 (0.7) |
35 (22.6) |
110 (71.0) |
145 (93.6) |
Pollen |
300 |
16 (5.3) |
0 (0) |
7 (2.3) |
43 (14.3) |
93 (31.0) |
141 (47.0) |
234 (78.0) |
Total |
596 |
18 (3.0) |
0 (0) |
29 (4.9) |
48 (8.1) |
194 (32.6) |
307 (51.5) |
501 (84.0) |
Group: Tested group
DD: Dust and dander group.
Mold: Mold group.
Pollen: Pollen group, including trees, grasses and weeds
Total: all values together. The total in this table is higher than the total of DRs as some occurred in more than one dilution
#T: Number of tests available for analysis
D6 (%) – D1 (%): Number of delayed reactions in each dilution (percentage). 6 is the weakest dilution. 1 is the strongest dilution
D1 + D2 (%): Number of DRs in Dilutions #1 and #2 combined (percentage over #T)
Table 4. Diameter of Delayed Reaction in Comparison to Immediate Skin Reaction
Group (# DR) |
DR< (%) |
DR> (%) |
DR= (%) |
|---|---|---|---|
DD (122) |
43 (35.2) |
42 (34.4) |
37 (30.3) |
Mold (149) |
70 (47.0) |
37 (24.8) |
42 (28.2) |
Pollen (300) |
164 (54.7) |
60 (20.0) |
76 (25.3) |
Totals (571) |
278 (48.7) |
143 (25.0) |
154 (27.0) |
Group (# DR): Tested group (number of Delayed Reaction in that group)
DD: Dust and dander group.
Mold: Mold group.
Pollen: Pollen group, including trees, grasses and weeds
DR<: Number of cases when the diameter of the DR was smaller than the diameter of the wheal during skin test
DR>: Number of cases when the diameter of the DR was larger than the diameter of the wheal during skin test
DR=: Number of cases when the diameter of the DR was the same as the diameter of the wheal during skin test
NOTE: The wheal at the time of the skin test includes positive and negative skin tests.
When DRs occurred through more than one dilution, the one occurring at the strongest dilution was chosen.
Table 5. Delayed Reactions
Tests |
853 |
100.0 % |
|---|---|---|
Delayed reactions (DRs) |
222 |
26.0% |
24 Hours |
194 |
87.4% |
24 + 48 Hours |
136 |
61.3% |
Only at 48 hours |
28 |
12.6% |
Tests: individual tested allergens available for evaluation
DRs: Number of Delayed Reactions in the whole group
24 Hours: Number of delayed reactions present at 24 hours
24 + 48 Hours: Number of delayed reactions present at 48 hours
Only at 48 Hours: Number of delayed reactions present at 48 hours but not at 24 hours
Abbreviation List
ISR: Immediate Skin Response
LSR: Late Skin Response
DSR: Delayed Skin Response
DR Delayed Reaction
LAR: Local Arm Reaction
NO BIO in 2019









0 Comments